Insider Stock Trading History of Mahatme Sandesh


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Mahatme Sandesh since year 2005. The trader's CIK number is 1511034. At the time of this reporting, Mahatme Sandesh is the EVP, CFO & CBO of Sarepta Therapeutics, Inc. . (stock ticker symbol SRPT). See this page for all insider trading activities at Sarepta Therapeutics, Inc. .


Stock purchases, sales, and option exercises reported by insider Mahatme Sandesh since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2019-02-07 SRPT Sarepta Therapeutics, Inc. Option Ex 65,000 23.85 1,550,250
2019-02-07 SRPT Sarepta Therapeutics, Inc. Sale 65,000 145.00 9,425,000
2019-01-31 SRPT Sarepta Therapeutics, Inc. Sale 21,198 130.72 2,771,002
2019-01-30 SRPT Sarepta Therapeutics, Inc. Option Ex 43,802 16.29 713,665
2019-01-31 SRPT Sarepta Therapeutics, Inc. Option Ex 21,198 23.85 505,572
2019-01-30 SRPT Sarepta Therapeutics, Inc. Sale 43,802 130.00 5,694,260
2018-10-24 SRPT Sarepta Therapeutics, Inc. Option Ex 89,400 16.29 1,456,594
2018-10-24 SRPT Sarepta Therapeutics, Inc. Sale 107,524 127.74 13,735,115
2018-05-22 SRPT Sarepta Therapeutics, Inc. Option Ex 6,649 .00 0
2018-03-15 SRPT Sarepta Therapeutics, Inc. Option Ex 2,500 23.85 59,625
2017-08-03 SRPT Sarepta Therapeutics, Inc. Option Ex 13,298 .00 0
2017-07-20 SRPT Sarepta Therapeutics, Inc. Option Ex 50,000 17.15 857,649
2017-07-21 SRPT Sarepta Therapeutics, Inc. Option Ex 1,500 23.85 35,775
2017-07-20 SRPT Sarepta Therapeutics, Inc. Sale 50,000 41.00 2,050,000
2016-11-09 SRPT Sarepta Therapeutics, Inc. Option Ex 1,000 23.85 23,850
2016-10-17 SRPT Sarepta Therapeutics, Inc. Option Ex 30,000 13.90 417,000
2016-10-17 SRPT Sarepta Therapeutics, Inc. Sale 30,000 50.08 1,502,490
2013-08-20 SRPT Sarepta Therapeutics, Inc. Buy 5,000 31.10 155,500

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mahatme Sandesh (EVP, CFO & CBO of Sarepta Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.